This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Johnson & Johnson (JNJ)

Tipranks - Tipranks - Sat Jul 25, 9:10AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Johnson & Johnson (JNJ) and NewAmsterdam Pharma Company (NAMS) with bullish sentiments.

Claim 55% Off TipRanks

Merck & Company (MRK)

Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company yesterday and set a price target of $137.00. The company’s shares closed last Friday at $130.67, close to its 52-week high of $134.63.

According to TipRanks.com, Haider is a 5-star analyst with an average return of 25.2% and a 86.0% success rate. Haider covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Bristol-Myers Squibb, and Johnson & Johnson. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $136.35, which is a 3.7% upside from current levels. In a report issued on July 8, RBC Capital also maintained a Buy rating on the stock with a $142.00 price target.

See today’s best-performing stocks on TipRanks >>

Johnson & Johnson (JNJ)

Scotiabank analyst Louise Chen maintained a Buy rating on Johnson & Johnson today and set a price target of $305.00. The company’s shares closed last Friday at $261.90.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 4.7% and a 48.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Teva Pharmaceutical. ;'>

Currently, the analyst consensus on Johnson & Johnson is a Strong Buy with an average price target of $279.19, implying a 6.8% upside from current levels. In a report released today, TipRanks – Anthropic also upgraded the stock to Buy with a $286.00 price target.

NewAmsterdam Pharma Company (NAMS)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on NewAmsterdam Pharma Company today and set a price target of $52.00. The company’s shares closed last Friday at $30.36.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 23.5% and a 54.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, Cadrenal Therapeutics, Inc., and Actinium Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $50.29 average price target, which is a 62.9% upside from current levels. In a report issued on July 21, BMO Capital also initiated coverage with a Buy rating on the stock with a $58.00 price target.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).